A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRuijin Hospital
About this trial
Evaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
Eligibility criteria
Qualifiers
1. Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity;
2. Simultaneous expression of MYC and BCL2, according to the WHO standard for immunohistochemistry: MYC ≥ 40%, BCL2 ≥ 50%
3. Age ≥ 18 years old and ≤ 75 years old;
4. ECOG performance status score of 0, 1, or 2;
Disqualifiers
1. Have previously received systemic or local treatments, including chemotherapy;
2. Have previously undergone autologous stem cell transplantation;
3. Previously had a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;
4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc;
Trial design
Treatments tested in this trial
- C-Pola-R-CHP+X
- CR-CHOP
Treatment groups
156 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov